Frontiers and hot topics in tumor metabolic reprogramming: a bibliometric analysis from 2014 to 2023 [0.03%]
2014—2023年肿瘤代谢重编程研究前沿与热点論文計量分析
Ping Wen,Guanwen Wang,Ningning Zhang et al.
Ping Wen et al.
Introduction: Tumor metabolic reprogramming refers to the alteration of metabolic pathways and patterns by tumor cells to adapt to various environmental conditions and energy demands, thereby playing a pivotal role in tum...
Deep learning-based risk stratification of ductal carcinoma in situ using mammography and abbreviated breast magnetic resonance imaging [0.03%]
基于深度学习的乳腺导管原位癌的风险分层（采用钼靶和简略乳腺磁共振成像）
Tingfeng Zhang,Tingting Cui,Zhenjie Cao et al.
Tingfeng Zhang et al.
Background: Current management of ductal carcinoma in situ lacks robust risk stratification tools, leading to universal surgical and radiotherapy interventions despite heterogeneous progression risks. Optimizing therapeut...
Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis [0.03%]
Sacituzumab govitecan治疗实体瘤的疗效和安全性：系统性回顾和荟萃分析
Yaping Zhang,Jian Chen,Xiaoyan Wang et al.
Yaping Zhang et al.
Background: Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) that targets trophoblast cell-surface antigen 2 and is conjugated to SN-38, a potent topoisomerase I inhibitor. SG has demonstrated promising acti...
Editorial: Challenges to research on oral potentially malignant disorders and oral cancer [0.03%]
论著：口腔癌前病变和口腔癌研究的挑战
Alberto Rodríguez-Archilla,Luis Alberto Gaitán-Cepeda
Alberto Rodríguez-Archilla
Research trends of protein palmitoylation in cancer from 2004 to 2024: a bibliometric and visualization analysis [0.03%]
2004-2024年肿瘤蛋白棕榈酰化的研究热点及趋势：基于文献计量和知识图谱的分析
Yufeng Peng,Kewei Peng,Yi Wang et al.
Yufeng Peng et al.
Background: Protein palmitoylation is a dynamic and reversible lipid modification that has attracted increasing attention in cancer research in recent years. Palmitoylation involves the covalent attachment of palmitic aci...
Molecular markers for the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma [0.03%]
头颈鳞癌新辅助免疫治疗疗效的分子标志物研究
Jiabin Zhu,Yudong Ning
Jiabin Zhu
Cancer ranks among the most formidable diseases. Currently, the treatment of malignant tumors has entered the immunotherapy era. Immunotherapy has achieved remarkable progress in treating malignant tumors, including head neck squamous cell ...
Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management [0.03%]
BRCA相关乳腺癌在亚太地区第2部分：临床管理共识声明和专家建议
Yeon Hee Park,Soo Chin Lee,Christian F Singer et al.
Yeon Hee Park et al.
Introduction: Existing guidelines have practical gaps in decision and treatment sequencing for BRCA germline pathogenic variant breast cancers. This paper aims to develop clinical-practice consensus guidelines to address ...
Tianyu Zhang,Ruyuan He,Yongguang Xiao
Tianyu Zhang
Esophageal cancer (EC) has been widely concerned because of its high incidence, high mortality and high recurrence rate. However, the traditional surgical treatment of EC has poor prognosis and high recurrence rate. Malnutrition is the most...
Hybrid model for predicting microsatellite instability in colorectal cancer using hematoxylin & eosin-stained images and clinical features [0.03%]
基于HE染色图像和临床特征的结直肠癌微卫星不稳定性预测 hybrid 模型
Hangping Wei,Xiaowei Zhang,Zhen Zhou et al.
Hangping Wei et al.
Background: Microsatellite instability (MSI) is a crucial molecular phenotype in colorectal cancer (CRC), which aids in determining treatment strategies and predicting prognosis. However, existing prediction methods have ...
Part I: consensus statements and expert recommendations for HER2-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessment [0.03%]
第一部分：亚洲-太平洋地区HER2阴性早期乳腺癌的共识声明和专家建议：诊断和风险评估
Soo Chin Lee,Yeon Hee Park,Christian F Singer et al.
Soo Chin Lee et al.
Introduction: In the Asia-Pacific region, there is increasing contention on the practical challenges involved in managing human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC). This modified D...